Co-Authors
This is a "connection" page, showing publications co-authored by DAVID G MENTER and KANWAL PRATAP SINGH RAGHAV.
Connection Strength
0.763
-
Validation of HER2 Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. JCO Precis Oncol. 2019 Dec; 3:1-13.
Score: 0.177
-
MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. 2016 08 23; 7(34):54627-54631.
Score: 0.141
-
Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer. JAMA Netw Open. 2022 10 03; 5(10):e2236357.
Score: 0.054
-
Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. Clin Cancer Res. 2021 06 01; 27(11):3039-3049.
Score: 0.049
-
Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. Br J Cancer. 2019 09; 121(6):505-510.
Score: 0.043
-
Clinical and molecular characterization of early-onset colorectal cancer. Cancer. 2019 06 15; 125(12):2002-2010.
Score: 0.042
-
Arginine methylation of EGFR: a new biomarker for predicting resistance to anti-EGFR treatment. Am J Cancer Res. 2017; 7(12):2587-2599.
Score: 0.039
-
Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clin Cancer Res. 2018 03 01; 24(5):1062-1072.
Score: 0.038
-
Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. Ann Surg Oncol. 2017 Dec; 24(13):4051-4058.
Score: 0.038
-
FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget. 2017 Jun 13; 8(24):39268-39279.
Score: 0.037
-
Modeling of Patient-Derived Xenografts in Colorectal Cancer. Mol Cancer Ther. 2017 07; 16(7):1435-1442.
Score: 0.037
-
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2017 Aug 01; 23(15):4146-4154.
Score: 0.037
-
Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer. 2015 Mar 17; 112(6):1088-97.
Score: 0.032